Utilisation préclinique de radiation focale et de l'inhibition du point de contrôle immunitaire pour améliorer la réponse thérapeutique dans une tumeur « froide » d'un point de vue immunologique

AUTEURS :

Maryland Rosenfeld Franklin, David Draper, Sumithra Urs, and Scott Wise

ANNÉE :

 2019

Réunion annuelle de l'AACR

POSTER | "Preclinical Use of Focal Radiation and Immune Checkpoint Blockade to Improve Therapeutic Response in an Immunologically Cold Tumor" (PDF)

Télécharger

 

Introduction et contexte

  • Radiation therapy (RT) is a highly utilized clinical treatment modality with more than 50 % of all cancer patients receiving some type of radiotherapy during the course of their illness. Appropriate systems and models to test preclinical radiation combinations are needed.
  • In mouse models, radiation treatment has been shown to increase the level of tumor antigen presentation and the variety of peptides available for cross-presentation. Current work in the field focuses on using radiation as a tool to bridge the gap from tumor equilibrium to tumor elimination, which could improve the response rate of immuno-oncology agents.
  • 4T1 is a murine breast cancer model known to have a large percentage of myeloid derived suppressor cells (MDSC) making the model resistant to many immunotherapies and is considered an immunologically cold tumor.
  • We hypothesized that treatment with focal radiation would sensitize 4T1 tumors to anti-mCTLA-4 treatment.